Caris Life Sciences,�Inc.

CAI Healthcare Biotechnology

Caris Life Sciences,�Inc.’s revenue for fiscal 2025 (year ended December 2025) was $812.0 million, up 97.0% from fiscal 2024. In the quarter to June 2026, revenue grew 45.4%, EPS grew 100.0%, free cash flow grew 8.47% and total debt rose 5.20%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

30.56 1.20 −3.78%
Market cap
$9.0B
P/E
81.3×
Fwd P/E
163×
Dividend yield
—
F-score
n/a
Altman Z
3.55
Beneish M
−2.71
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
ROE
15.45% 45.75% 0.00% 0.00%

+6 more TTM periods

ROA
7.39% (75.00%) (95.58%) (139.72%)
ROIC
49.95% 44.67% 18.05% (66.54%)
Return on Tangible Assets
8.39% (45.74%) (57.61%) (82.65%)
Average Days of Receivables
43.11 36.41 50.41 15.70
Free Cash Flow per Share
0.44 0.44 0.40 (0.05)
Free Cash Flow
123.96 123.46 66.90 (14.01)
Other line items

Show all line items

Columns are period end dates